Navigation Links
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Date:3/7/2008

877-852-6578 (U.S.), 1-719-325-4794 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401, which is currently in Phase 2 clinical development for multiple tumor types, is expected to move into a Phase 3 clinical program in 2008. The Company also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates.

Cautionary Statement

As the Company has indicated in its public filings, among other things, clinical trials have a high risk of failure. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving what appeared to be promising results in earlier trials.

Furthermore, as indicated in previous fili
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Foot Care ... Medication. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
Breaking Medicine Technology:Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15Global Foot Care Products Industry 16Global Foot Care Products Industry 17Global Foot Care Products Industry 18Global Foot Care Products Industry 19Global Foot Care Products Industry 20Global Foot Care Products Industry 21Global Foot Care Products Industry 22Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3
... N.J., May 24, 2012 Watson Pharmaceuticals, Inc. ... its subsidiary, Watson Laboratories, Inc., filed an Abbreviated ... and Drug Administration (FDA) seeking approval to market ... is a generic version of Auxilium Pharmaceuticals, Inc.,s ...
... ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An ... Life Science Venture Forum in Houston, Texas named TransCU ... of ten Most Promising Life Science Technologies .  ... and innovations to hundreds of early-stage investors, venture capitalists, ...
Cached Medicine Technology:Watson Confirms Testim® Patent Challenge 2Watson Confirms Testim® Patent Challenge 3New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event 2
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Regulatory ... available regulatory information, has become a crucial skill ... device and biotechnology sectors. Regulatory Intelligence 101 ... Society (RAPS) serves as an essential guide ... Regulatory Intelligence 101 examines available regulatory intelligence tools, ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
(Date:9/16/2014)... San Francisco, September 15, 2014Patients with inoperable, early-stage ... (SBRT) have a five-year survival rate of 40 ... American Society for Radiation Oncology,s (ASTRO,s) 56th Annual ... considering that historically conventional RT resulted in poor ... This study is an update of RTOG 0236, ...
(Date:9/16/2014)... of researchers at Boston University and Stanford University School ... the motion patterns of bacteria in real time and ... a bacterial colony. , The researchers chemically attached colonies ... a microscopic beam anchored at one end, similar ... to that of the bacteria. As the cantilever itself ...
Breaking Medicine News(10 mins):Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:And so they beat on, flagella against the cantilever 2
... kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting ... panel of human tumor cell lines in vitro: Abstract ... designed to inhibit a single protein that functions only ... range of cancer cell lines, say researchers from GlaxoSmithKline. ...
... Pharmaceuticals, a New,Jersey-based developer, manufacturer and distributor ... API and finished,dosages development and manufacturing company ... to develop, manufacture, market and distribute,several products ... product pipeline,will include at least ten ophthalmic ...
... Members of Congress Call Today for a "Medicare-Operated" ... adults and persons,with disabilities should have the option ... program to eliminate the consumer,exploitation that plagues the ... insurance companies, concludes Consumers Union and the Medicare,Rights ...
... Standards Panel (HITSP) has identified a set of,standards ... medical,information secure in an electronic environment. The standards ... only be used by authorized,personnel for official purposes., ... and privacy architecture is,the latest in a series ...
... medical care, researchers suggest , , TUESDAY, Oct. 23 (HealthDay News) ... remained constant since 2000, with some one-third of all Americans ... , But less than 25 percent of those at high ... sex or are intravenous drug users -- have been tested ...
... Affordable Treatments for the World,s ... episode of the Charlie Rose Science Series will ... -- ranging from the AIDS crisis to malaria, ... neglected diseases. A group of experts ...
Cached Medicine News:Health News:Experimental cancer pharmaceuticals under trial 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 3Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 2Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 3Health News:HITSP Defines Overarching Set of Healthcare Security and Privacy Standards 2Health News:Many at Risk for HIV Not Being Tested 2Health News:Many at Risk for HIV Not Being Tested 3Health News:Charlie Rose Science Series Episode #10 - GLOBAL HEALTH October 29, 2007 2
... KIMBERLY-CLARK CLOtest Rapid Urease Test is ... Standard among urease tests because of its ... by Barry Marshall, MD. who, along with ... discover the correlation between H. pylori and ...
... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
... pylori WB test is a ... detection of lgG antibodies specific ... whole blood. This test kit ... in the diagnosis of H.pylori ...
... based on a lateral flow chromatography ... the qualitative detection of Helicobacter pylori ... Platinum HpSA, a microtiter assay from ... accepted as an accurate tool for ...
Medicine Products: